Back to results

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

Primary Purpose

Pancreatic Cancer

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

sirolimus

About this trial

This is an interventional treatment trial for Pancreatic Cancer focused on measuring recurrent pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, adenocarcinoma of the pancreas

Eligibility Criteria

18 Years - 120 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

Inclusion criteria:

Histologically proven adenocarcinoma of the pancreas
- Locally-advanced or advanced disease which has progressed after one prior gemcitabine-containing regimen
Unidimensionally measurable disease (defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan) OR evaluable disease
Tumor tissue available for IHC assessment OR willingness to undergo a safe biopsy of tumor tissue

Exclusion criteria:

Histologic or cytologic diagnosis that is not consistent with adenocarcinoma, including adenosquamous, islet cell, cystadenoma or cystadenocarcinoma, carcinoid, or small or large cell carcinoma or lymphoma
Adenocarcinoma arising from a site other than the pancreas (e.g., distal common bile duct, ampulla of vater or periampullary duodenum)
Known brain metastases

PATIENT CHARACTERISTICS:

Inclusion criteria:

ECOG performance status 0-1
WBC > 3,500 cells/mm³
ANC > 1,500 cells/mm³
Hemoglobin > 9 g/dL
Serum creatinine ≤ 2.0 mg/dL
Bilirubin ≤ 2 mg/dL
ALT, AST, and alkaline phosphatase ≤ 5 times upper limit of normal
Triglycerides and total cholesterol < 2 times upper limit of normal
Not pregnant or nursing

Exclusion criteria:

Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy, including immunodeficiency and chronic treatment with immunosuppressors
Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease
Active infections
History of concurrent malignancy or history of a second malignancy within the past 5 years
Clinically significant cardiovascular disease, including myocardial infarction (within 12 months prior to randomization), unstable angina, grade II or greater peripheral vascular disease, uncontrolled congestive heart failure, or uncontrolled hypertension (i.e., systolic blood pressure (BP) > 170 mm Hg, diastolic BP > 95 mm Hg)

PRIOR CONCURRENT THERAPY:

Exclusion criteria:

Any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy
Any previous surgery, excluding minor procedures (e.g., dental work or skin biopsy) within 4 weeks of enrollment
Participation in an investigational new drug trial within 1 month of starting trial
Treatment with chemotherapy within 30 days of day 1 treatment
At least 10 days since prior and no concurrent:
- Cyclosporine
- Diltiazem
- Ketoconazole
- Rifampin
- St. Johns wort
- Grapefruit juice
Concurrent phenytoin, carbamazepine, barbiturates, or phenobarbital
No other concurrent investigational or commercial agents

Sites / Locations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sirolimus

Arm Description

Sirolimus 5mg. po QD continously (28 days=cycle)

Outcomes

Primary Outcome Measures

Percentage of Patients With Overall Survival at 6 Months

Response Rate (Complete, Partial Response and Stable Disease) as Assessed by RECIST

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progression, a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Response for Stable disease was assessed at 2 months and for complete and partial response at 6 months.

Severity of Adverse Events as Assessed by NCI CTCAE v3.0

Secondary Outcome Measures

Full Information

NCT ID

NCT00499486

First Posted

July 10, 2007

Last Updated

October 18, 2016

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

National Cancer Institute (NCI)

1. Study Identification

Unique Protocol Identification Number

NCT00499486

Brief Title

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

Official Title

Phase II Clinical, Biological and Pharmacological Study of Rapamycin (Rapamune®, Sirolimus) in Patients With Advanced Pancreatic Cancer

Study Type

Interventional

2. Study Status

Record Verification Date

October 2016

Overall Recruitment Status

Completed

Study Start Date

January 2005 (undefined)

Primary Completion Date

September 2008 (Actual)

Study Completion Date

June 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well sirolimus works in treating patients with advanced pancreatic cancer.

Detailed Description

OBJECTIVES: Primary To determine the proportion of patients with previously treated advanced pancreatic cancer surviving at 6 months after treatment with single agent rapamycin. To evaluate the relationship between activation of the PI3/Akt/mTOR/S6K signaling pathway in tumor tissues and rapamycin activity in this patient population. To characterize toxicity of rapamycin in this patient population. Secondary To determine the response rate, median time to treatment failure, and median survival of patients with previously treated advanced pancreatic cancer who are treated with single agent rapamycin. To characterize the pharmacokinetics of rapamycin in this patient population. To explore pharmacogenomic variables that affect rapamycin pharmacokinetics and clinical activity in this patient population. To determine the pharmacodynamic effects of rapamycin on S6 kinase activation in PBMC, normal skin, and normal oral mucosa obtained from patients treated with the drug and its relationship with rapamycin pharmacokinetics and clinical effects. To explore biomarkers in tumor tissues that might be associated with rapamycin clinical effects. OUTLINE: Patients receive oral sirolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood, normal skin, and tumor tissue collection at baseline and periodically during study for pharmacological, biological, and genotyping studies. Blood samples are analyzed by LC/MS/MS assay to assess rapamycin pharmacokinetics (PKs) during courses 1 and 2 and to determine baseline CYP3A4 activity. Samples are also analyzed by genotyping studies to assess CYP3A4 polymorphisms. Pharmacodynamic activity of rapamycin is assessed in peripheral blood mononuclear cells isolated from PK blood samples using a kinase assay to measure S6K activity. Tumor tissue is collected from pretreatment tumor samples obtained at the time of diagnosis or surgery or by biopsy from patients for whom pre-study tumor specimens are not available. Patients undergo skin biopsies at baseline and on day 1 of course 2 to obtain samples of normal skin. Patients also undergo oral mucosa smears at baseline and weekly during course 1. Tumor tissue, normal skin, and oral mucosa samples are assessed by IHC staining of S6K and p-S6K and by RT-PCR for cyclin D1 and p27.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pancreatic Cancer

Keywords

recurrent pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, adenocarcinoma of the pancreas

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

47 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Sirolimus

Arm Type

Experimental

Arm Description

Sirolimus 5mg. po QD continously (28 days=cycle)

Intervention Type

Drug

Intervention Name(s)

sirolimus

Other Intervention Name(s)

rapamycin

Intervention Description

Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.

Primary Outcome Measure Information:

Title

Percentage of Patients With Overall Survival at 6 Months

Time Frame

6- month survival rate (6mSR)

Title

Response Rate (Complete, Partial Response and Stable Disease) as Assessed by RECIST

Description

Time Frame

response at 2 and 6 months

Title

Severity of Adverse Events as Assessed by NCI CTCAE v3.0

Time Frame

6 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

120 Years

Accepts Healthy Volunteers

Eligibility Criteria

DISEASE CHARACTERISTICS: Inclusion criteria: Histologically proven adenocarcinoma of the pancreas Locally-advanced or advanced disease which has progressed after one prior gemcitabine-containing regimen Unidimensionally measurable disease (defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan) OR evaluable disease Tumor tissue available for IHC assessment OR willingness to undergo a safe biopsy of tumor tissue Exclusion criteria: Histologic or cytologic diagnosis that is not consistent with adenocarcinoma, including adenosquamous, islet cell, cystadenoma or cystadenocarcinoma, carcinoid, or small or large cell carcinoma or lymphoma Adenocarcinoma arising from a site other than the pancreas (e.g., distal common bile duct, ampulla of vater or periampullary duodenum) Known brain metastases PATIENT CHARACTERISTICS: Inclusion criteria: ECOG performance status 0-1 WBC > 3,500 cells/mm³ ANC > 1,500 cells/mm³ Hemoglobin > 9 g/dL Serum creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2 mg/dL ALT, AST, and alkaline phosphatase ≤ 5 times upper limit of normal Triglycerides and total cholesterol < 2 times upper limit of normal Not pregnant or nursing Exclusion criteria: Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy, including immunodeficiency and chronic treatment with immunosuppressors Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease Active infections History of concurrent malignancy or history of a second malignancy within the past 5 years Clinically significant cardiovascular disease, including myocardial infarction (within 12 months prior to randomization), unstable angina, grade II or greater peripheral vascular disease, uncontrolled congestive heart failure, or uncontrolled hypertension (i.e., systolic blood pressure (BP) > 170 mm Hg, diastolic BP > 95 mm Hg) PRIOR CONCURRENT THERAPY: Exclusion criteria: Any unresolved chronic toxicity greater than CTCAE grade 2 from previous anticancer therapy Any previous surgery, excluding minor procedures (e.g., dental work or skin biopsy) within 4 weeks of enrollment Participation in an investigational new drug trial within 1 month of starting trial Treatment with chemotherapy within 30 days of day 1 treatment At least 10 days since prior and no concurrent: Cyclosporine Diltiazem Ketoconazole Rifampin St. Johns wort Grapefruit juice Concurrent phenytoin, carbamazepine, barbiturates, or phenobarbital No other concurrent investigational or commercial agents

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Manuel Hidalgo, MD, PhD

Organizational Affiliation

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Official's Role

Principal Investigator

Facility Information:

Facility Name

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21231-2410

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Citations:

PubMed Identifier

20664591

Citation

Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer. 2010 Aug 24;103(5):649-55. doi: 10.1038/sj.bjc.6605819. Epub 2010 Jul 27.

Results Reference

result

Learn more about this trial

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

We'll reach out to this number within 24 hrs